BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23464468)

  • 1. Overexpression of her-2/neu in malignant mammary tumors; translation of clinicopathological features from dog to human.
    Muhammadnejad A; Keyhani E; Mortazavi P; Behjati F; Haghdoost IS
    Asian Pac J Cancer Prev; 2012; 13(12):6415-21. PubMed ID: 23464468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study.
    Kim JH; Im KS; Kim NH; Yhee JY; Nho WG; Sur JH
    Vet J; 2011 Sep; 189(3):318-22. PubMed ID: 20947393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.
    Harbeck N; Ross JS; Yurdseven S; Dettmar P; Pölcher M; Kuhn W; Ulm K; Graeff H; Schmitt M
    Int J Oncol; 1999 Apr; 14(4):663-71. PubMed ID: 10087312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of HER-2/neu receptor positivity and its association with other features of breast cancer.
    Naeem M; Nasir A; Aman Z; Ahmad T; Samad A
    J Ayub Med Coll Abbottabad; 2008; 20(3):23-6. PubMed ID: 19610508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study.
    Martin de las Mulas J; Ordás J; Millán Y; Fernández-Soria V; Ramón y Cajal S
    Breast Cancer Res Treat; 2003 Aug; 80(3):363-7. PubMed ID: 14503809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma.
    Pujani M; Makker I; Makker A; Jetley S; Goel MM; Jetley S
    Asian Pac J Cancer Prev; 2016; 17(8):3903-9. PubMed ID: 27644637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
    Nguyen F; Peña L; Ibisch C; Loussouarn D; Gama A; Rieder N; Belousov A; Campone M; Abadie J
    Breast Cancer Res Treat; 2018 Feb; 167(3):635-648. PubMed ID: 29086231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer.
    Depowski PL; Brien TP; Sheehan CE; Stylos S; Johnson RL; Ross JS
    Am J Clin Pathol; 1999 Oct; 112(4):459-69. PubMed ID: 10510669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological significance of lymphangiogenesis and tumor lymphovascular invasion in indonesian breast cancers.
    Widodo I; Ferronika P; Harijadi A; Triningsih FE; Utoro T; Soeripto
    Asian Pac J Cancer Prev; 2013; 14(2):997-1001. PubMed ID: 23621275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-erbB-2 expression and nuclear pleomorphism in canine mammary tumors.
    Dutra AP; Granja NV; Schmitt FC; Cassali GD
    Braz J Med Biol Res; 2004 Nov; 37(11):1673-81. PubMed ID: 15517084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
    Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
    Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
    Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
    Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of HER2 expression in canine mammary tumors by antibody-based, transcriptomic and mass spectrometry analysis: is the dog a suitable animal model for human breast cancer?
    Burrai GP; Tanca A; De Miglio MR; Abbondio M; Pisanu S; Polinas M; Pirino S; Mohammed SI; Uzzau S; Addis MF; Antuofermo E
    Tumour Biol; 2015 Nov; 36(11):9083-91. PubMed ID: 26088453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor characteristics and metabolic quantification in carcinoma breast: An institutional experience.
    Dubey IP; Jain A; Chauhan MS; Kumar R; Agarwal S; Kishore B; Vishnoi MG; Paliwal D; John AR; Kumar N; Sharma A; Pandit AG
    Indian J Cancer; 2017; 54(1):333-339. PubMed ID: 29199717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
    Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.